SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release relating to Earnings Call for financial results for the second quarter and first half ending September 30, 2020. Sun Pharmaceutical Industries Ltd - 524715 - Board Meeting Intimation for Notice Of The Board Meeting For Consideration And Approval Of Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended September 30, 2020
SUN PHARMACEUTICAL INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2020 ,inter alia, to consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2020. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Shareholding for the Period Ended September 30, 2020
Sun Pharmaceutical Industries Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2020. For more details, kindly Click here SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 19, 2020 for Raksha Sudhir Valia SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Statement Of Investor Complaints For The Quarter Ended September 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0110 Name of the Signatory :- Ashok BhutaDesignation :- Any Other SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliance Certificate Under Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Please find enclosed Compliance Certificate under Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Clarifies on News item
The Exchange has sought clarification from Sun Pharmaceutical Industries Ltd with respect to news article appearing on the hindubusinessline.com dated October 14, 2020 titled "SEBI probing role of Sun Pharma ex-board member Ashwin Dani". Link:https://www.thehindubusinessline.com/markets/stock-markets/sebi-probing-role-of-sun-pharma-ex-board-member-ashwin-dani/article32856401.ece Sun Pharmaceutical Industries Ltd in its reply dated October 15, 2020 has stated following: "Sun Pharma has not received any information or notice either from SEBI or anyone regarding the matter. Hence we are not aware of the matter." SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliance Certificate Under Regulation 7 (3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Please find enclosed Compliance Certificate - Regulation 7 (3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
USFDA inspections taking longer time than usual due to COVID-19 safety protocols
Sun Pharma, Auro Life, Lupin in the queue. Though generally, most inspections are done in a fortnight, now it's taking almost a month. USFDA is taking precautions to ensure the safety of the investigators and the employees of the facility who assist its staff, say sources. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find enclosed Certificate under Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended 30th September, 2020